This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
November 10, 2022
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
November 10, 2022
Hubro Therapeutics AS acquires GM-CSF vaccine adjuvant from Targovax ASA in asset purchase agreement
November 09, 2022
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
November 09, 2022
Oncopeptides announces the market potential for Pepaxti in Europe
November 09, 2022
Oncopeptides publishes Q3 report 2022
November 09, 2022
Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results And Clinical Program Updates
November 03, 2022
Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21
November 03, 2022
Pulmonx Reports Third Quarter 2022 Financial Results
November 03, 2022
Interim report July-September 2022
November 03, 2022
Targovax ASA: Third quarter 2022 results